Abstract IA020: The gut microbiome in colorectal cancer


 The gut microbiome plays important roles in colorectal cancer (CRC) initiation, treatment, and survivorship. This talk will highlight preliminary results from two pilot studies: Gut microbiome & Oral fluoropyrimidines (GO) and Lifestyle and Outcome in Gastrointestinal Cancer (LOGIC). GO investigated the impact of oral fluoropyrimidines (e.g., capecitabine) on gut microbes via longitudinal stool sampling. Despite marked inter- and intra-individual differences in diversity and community structure, we detected multiple consistent taxonomic differences. LOGIC asked: how do diet and lifestyle, measured by the American Cancer Society (ACS) score, correlate with gut microbiota characteristics in CRC survivors? We found that components of the ACS score related to fruit and vegetable consumption, but not the overall ACS score, significantly associated with variations in microbial community structures, diversity, and differences in abundance of microorganisms at various taxonomic levels. Practical considerations influencing the design of follow-up studies in progress will be discussed.
 Citation Format: Chloe E. Atreya. The gut microbiome in colorectal cancer [abstract]. In: Proceedings of the AACR Special Conference on Colorectal Cancer; 2022 Oct 1-4; Portland, OR. Philadelphia (PA): AACR; Cancer Res 2022;82(23 Suppl_1):Abstract nr IA020.